Health & Environmental Research Online (HERO)


Print Feedback Export to File
7143015 
Journal Article 
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group 
Jones, S; Vogel, C; Arkhipov, A; Fehrenbacher, L; Eisenberg, P; Cooper, B; Honig, S; Polli, A; Whaley, F; di Salle, E; Tiffany, J; Consonni, A; Miller, L; , 
1999 
Yes 
Journal of Clinical Oncology
ISSN: 0732-183X
EISSN: 1527-7755 
English 
10550136 
To assess the antitumor activity, safety, and hormone-suppressive effects of the irreversible aromatase inactivator, exemestane (Aromasin, Pharmacia & Upjohn, Kalamazoo, MI), administered as third-line hormone therapy to postmenopausal women with metastatic breast cancer that is refractory to tamoxifen and megestrol acetate.